Oral testosterone ester

Testosterone Undecanoate (Oral)

Per the Tlando label, oral testosterone undecanoate is primarily absorbed into the lymph; the app uses a 6-hour half-life, that label gives about 2 hours for the ester, and a Restandol document about 7% bioavailability.2,4

Strong evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Testosterone Undecanoate (Oral) after one dose: 50% at ~6 h, 25% at 12 h, 12.5% at 18 h.

Drawn from the half-life in the app's model, ~6 h. The model's figures

Oral testosterone undecanoate is a capsule form of the testosterone ester testosterone undecanoate, sold in the US as Jatenzo, Tlando and Kyzatrex.1,2,3 The Irish summary of product characteristics for Restandol Testocaps, a 40 mg soft capsule, describes another oral testosterone undecanoate product.4 The app's notes name Andriol and Jatenzo as brand names.

Each of the three US labels states that its product is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone, and each states that safety and efficacy in men with “age-related hypogonadism” have not been established.1,2,3

The Strong Evidence tag is the app's own grade, and none of the sources cited here grades evidence. The primary endpoint of the Jatenzo pivotal trial was the percentage of patients with a 24-hour average plasma total testosterone concentration in the normal range, and Swerdloff and colleagues write that the efficacy of testosterone replacement products in the US is based solely on testosterone pharmacokinetic parameters.1,5

The Tlando label states that testosterone undecanoate “is a lipophilic molecule that is primarily absorbed into the lymph system after oral administration” and is released into the general blood circulation by the thoracic duct, “avoiding absorption into the portal vein thereby circumventing first-pass metabolism in the liver”.2

The Restandol document states that “an important part” of the active substance is co-absorbed with the lipophilic solvent into the lymphatic system, “thus partially circumventing the first-pass inactivation by the liver”.4

The Jatenzo label states that the androgenic activity of testosterone undecanoate occurs after the ester bond is cleaved by endogenous non-specific esterases, and that the major active metabolites of testosterone are dihydrotestosterone (DHT) and estradiol.1

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~6 h
Bioavailability
7%
Typical dose
120–240 mg
Route
Oral
Time to peak
~4 h

The app's figures for oral testosterone undecanoate are a half-life of about 6 hours, a bioavailability of 7% and a time to peak of about 4 hours.

Table 3.1Half-life and pharmacokinetics7 rows
MeasureFigureSource and note
Elimination half-life of testosterone undecanoateApproximately 2 hoursTlando label statement.2
Half-life of testosterone once formed from the ester10 to 100 minutesTlando label: “considerable variation in the half-life of testosterone as reported in the literature”.2
Elimination half-life of testosterone after 28 days of 200 mg twice dailyMedian 18.4 hours (mean 29 hours)Yin and colleagues, 2012: 200 mg as testosterone equivalents with food, one morning dose on day 28; evaluable in about half of the 15 men in that part; Clarus Therapeutics developed the formulation and supported the study.6
BioavailabilityAbout 7%Restandol summary of product characteristics, Absorption section, which states that a normal meal or breakfast is needed to ensure absorption.4
Peak after a single 80 to 160 mg dose of RestandolAbout 40 nmol/L of total plasma testosterone, about 4 to 5 hours after the doseThe same document states that plasma testosterone levels remain elevated for at least 8 hours.4
Time to peak after 225 mg of TlandoMedian about 5 hoursMean maximum serum testosterone 979 and 989 ng/dL after the morning and evening doses; 24-hour average 476 ng/dL; 95 hypogonadal males.2
Time to peak in the 2020 Jatenzo and 2025 Tlando trialsMedian 3.87 hours after the morning Jatenzo dose (range 0.00 to 12.08)Swerdloff and colleagues, 155 men at the final visit.5 In the Tlando trial, concentrations rose above the lower threshold within 2 hours of the morning dose and “peaked approximately 4–6 h later”.11

The Jatenzo and Kyzatrex label texts state no half-life in their pharmacokinetics sections, and the Restandol document, which describes Restandol and not the three US products, gives a bioavailability of about 7% that equals the app's figure.1,3,4 The app's 6-hour half-life differs from the Tlando label's 2 hours for the ester, from that label's 10 to 100 minutes for testosterone and from the 2012 study's 18.4 hours (median) for testosterone.2,6

Food effect

Yin and colleagues gave 16 hypogonadal men a single dose of 300 mg testosterone equivalents, fasting or after a meal of 10%, 20%, 30% or 50% fat, in a 5-way crossover study.7 The 20% and 50% fat meals did not differ significantly from the 30% fat meal; fasting gave “50% or less of the cumulative exposure” of the 20% to 50% fat meals “(albeit still substantial)”, and the 10% fat meal showed a significant food effect against the 30% fat meal but “still exceeded the fasting condition by approximately 50%”.7 At the 300 mg dose, meals of 20% to 50% fat produced testosterone “at or above the upper range of adult men”, and levels “trended higher as dietary fat content increased”.7 Clarus Therapeutics developed the formulation, two authors are its employees and one is a consultant.7

The labels report food effects too: a 15 g fat breakfast gave 25% lower exposure than a 30 g fat breakfast with Jatenzo (30 g, 45 g and high-fat breakfasts were comparable), fasting gave about 65% and 38% lower maximum concentration and area under the curve than a high-fat meal with Tlando (low, moderate and high-fat meals were comparable in 13 to 14 men), and fat breakfasts raised Kyzatrex exposure by 37% to 94% over fasting.1,2,3 In the Kyzatrex phase 3 trial, “Diet had no effect on participant eugonadal percentages”.12

Level curve between doses

The chart below draws a one-compartment model with the app's half-life of 6 hours and time to peak of about 4 hours, every 12 hours, the spacing used in the Jatenzo and Tlando trials and in line with the labels' one dose in the morning and one in the evening; it is an illustration, not a measured or predicted level for any person.1,2,3

Level over 3 days

Interval between doses

Level, as a share of the peak after one 200 mg dose

As studied: every 12 hours1.

An illustration from a pharmacokinetic model using a half-life of 6 hours. It is not a measured level or a suggested dose.

4

What oral testosterone undecanoate products contain per capsule

Table 4.1What oral testosterone undecanoate products contain per capsule4 rows
ProductMakerCapsule strengths
Jatenzo1Tolmar Inc.158 mg, 198 mg and 237 mg
Tlando2Verity Pharmaceuticals Inc.112.5 mg (the 225 mg dose is two capsules)
Kyzatrex3Marius Pharmaceuticals50 mg, 100 mg, 150 mg and 200 mg
Restandol Testocaps4Merck Sharp & Dohme Ireland (Human Health) Limited, authorisation holder40 mg (equivalent to 25.3 mg testosterone)
5

Human studies

Table 5.1Human studies6 rows
Study and yearDesignPeopleDose and lengthMain result
Skakkebaek and colleagues, 19818Double-blind crossover against placebo12 men with hypogonadism160 mg daily by mouthSignificant effect on all measures of sexual interest and behaviour; the rise in plasma testosterone was “modest, not reaching the normal range in several cases”.
Bouloux and colleagues, 20139Multicentre, double-blind, randomized, placebo-controlled, dose-ranging322 men aged 50 or older with testosterone deficiency symptomsPlacebo, or 80, 160 or 240 mg a day in divided doses with meals; 12 monthsBone mineral density rose against placebo at the lumbar spine and total hip (240 mg) and at the trochanter and intertrochanter (160 and 240 mg); lean body mass rose at months 6 and 12 in all oral groups.
Swerdloff and colleagues, 20205Phase 3, randomized 3:1, open-label, active-controlled (topical testosterone)221 hypogonadal men aged 18 to 65 (166 oral, 55 topical)Jatenzo from 237 mg twice daily, titrated; about 3 to 4 months87.3% of men in each arm had a 24-hour average testosterone in the normal range; 24-hour systolic pressure rose 4.9 mm Hg with oral and 0.2 mm Hg with topical.
White and colleagues, 2021 (Tlando)10Ambulatory blood pressure study; the Tlando label calls it uncontrolled2138 men with hypogonadism, mean age 54, 48% with hypertension225 mg twice daily; 4 months24-hour systolic pressure +3.8 mm Hg (P < 0.001), diastolic +1.2 mm Hg (P = 0.009) in the paper's summary, which does not say how many of the 138 men they cover (the Tlando label gives +4.3 and +1.4 for the 123 men with acceptable recordings); hematocrit +3.2%, hemoglobin +0.9 g/dL; in the top quartile of hematocrit change (6% to 14%) systolic pressure rose a mean 8.3 mm Hg, against 1.9, 3.3 and 2.1 in the other quartiles.
Miner and colleagues, 2025 (Tlando, SOAR)11Phase 3, randomized 2:1, open-label, active-controlled (1.62% topical gel)315 randomized: 210 oral, 105 gel225 mg twice daily, adjusted by 75 mg per dose at weeks 4 and 8; 52 weeks87.4% of the 151 men in the efficacy set had a 24-hour average testosterone of 300 to 1140 ng/dL at week 13; 130 of 210 oral patients completed; no deaths or treatment-related serious adverse events; nominal secondary gains over gel on SF-36 mental health (p = 0.035).
Bernstein and Dhingra, 2024 (Kyzatrex)12Phase 3, open-label, single-arm155 hypogonadal menFrom 200 mg twice daily, titrated to 100 to 800 mg daily; 180 daysEugonadal mean plasma testosterone in 87.8% (worst case) and 96.1% of 90-day completers; ambulatory systolic pressure +1.7 mm Hg; 14.7% above the hemoglobin upper limit at the final visit.

Clarus Therapeutics funded the Jatenzo trial, Lipocine funded the SOAR trial and Marius Pharmaceuticals sponsored the Kyzatrex trial, and Lipocine employees are among the authors of the Tlando blood pressure paper.5,11,13,10 The summary texts of the 1981 and 2013 studies state no funder and report no adverse events or discontinuations.8,9 The 1981 trial used a product from Organon International, and the 2013 trial enrolled men aged 50 or older; each US label states that safety and efficacy in “age-related hypogonadism” have not been established.1,2,3

Deeper analysis: the 2020 Jatenzo phase 3 trial

Swerdloff and colleagues reported the trial in 2020; Clarus Therapeutics supported it, two authors (Dudley and Danoff) are Clarus employees who own stock, and four others have been consultants for the company.5 The primary result was 87.3% of oral patients (145 of 166; 95% CI 81.3% to 92.0%) with a 24-hour average testosterone of 252 to 907 ng/dL in plasma.5 Peak serum-equivalent concentrations were 1500 ng/dL or below in 90.7% of oral patients (137 of 151); the Jatenzo label reports 83% and notes that its concentrations “were not measured in serum”, and the paper's own post hoc plasma figure was 82.8% at or below 1361 ng/dL, against a target of at least 85%.5,1

Related treatment-emergent adverse events occurred in 18.7% of oral and 14.5% of topical patients, with no deaths and no drug-related serious adverse events, and 1.8% in each group stopped for adverse events.5 Against topical testosterone the oral group had a larger rise in 24-hour systolic pressure (4.9 ± 8.7 versus 0.2 ± 9.4 mm Hg, P = 0.0013), hematocrit above the normal range in 3% versus none, and 5.9% starting or increasing antihypertensive medication, while the Jatenzo label gives 12 patients (7.2%) for the same trial.5,1

The authors write that “there exists the potential that oral TU may increase systolic BP in some men”, and that the number of patients was “relatively small” and oral treatment “fairly brief”.5

Deeper analysis: the 2025 Tlando phase 3 trial (SOAR)

Miner, Wang, Kaminetsky and colleagues reported the trial in 2025; Lipocine funded it, and Antares Pharma, a subsidiary of Halozyme Therapeutics, funded the medical writing.11 One author (Chidambaram) is a Lipocine employee, one (King) was formerly with Antares Pharma and holds Halozyme shares, and Miner and Khera report consulting for Halozyme, Khera also for Marius and Tolmar.11 Of 315 men randomized 2:1, early discontinuation was 38% (80 of 210) on oral testosterone undecanoate and 32% (34 of 105) on gel, and 130 (62%) of the oral group completed.11 The primary result was 87.4% (95% CI 81.7% to 92.7%) of the 151 men in the efficacy set within 300 to 1140 ng/dL at week 13, meeting the prespecified target of at least 75%; the efficacy set left out 42 of the 193 men in the oral full analysis set for major protocol deviations, generally non-compliance or incorrect titration.11 The target of at least 85% of men with a maximum concentration below 1500 ng/dL was not met for the full 24 hours (82.8%).11

Treatment-related events occurred in 24.3% (51 of 210) of the oral group and 22.1% (23 of 104) of the gel group and led to discontinuation in 11 oral patients (5.2%) and 3 gel patients (2.9%), with acne in 6 oral patients; two oral patients stopped for hematocrit above 54%, and sixteen patients had 27 severe events, none judged treatment-related.11 On nominal secondary endpoints oral treatment beat gel on SF-36 mental health (p = 0.035), mental component summary (p = 0.009) and weekly negative mood (p = 0.021).11 Mean HDL fell more on oral treatment than on gel (0.15 versus 0.05 mmol/L at week 52), all treatment-related hematocrit increases occurred in oral patients, and the paper reports no clinically meaningful trends in blood pressure with either treatment.11 The authors write that “At the recommendation of the FDA, only oral TU was included in the full analysis set”, so the comparison with gel on the primary endpoint “was not completed”.11

Deeper analysis: the 2024 Kyzatrex phase 3 trial

Bernstein and Dhingra reported the 6-month, single-arm trial in 2024, and White and colleagues its blood pressure results in 2021.12,13 Marius Pharmaceuticals funded the trial, and the authors “were employees of Marius Pharmaceuticals LLC during study conduct and retain financial interest in Marius”; White received consulting fees from Marius and Rittmaster is a former Marius consultant.12,13 In plasma, 96.1% of 90-day completers and 87.8% on the worst-case analysis were in the eugonadal range (139 men), against 87.5% and 86.5% in the 89-man serum sub-study; serum average testosterone was 452 ng/dL, and 135 of 155 men (87.1%) attended day 180; the paper lists 1.3% stopping for adverse events, while the Kyzatrex label names one patient (0.8%) stopping for acne.12,3 The paper also counts 6 men (3.9%) with a hypertension or blood pressure increase event, against the label's 4 (2.6%) for cuff hypertension.12,3 The paper reports no drug-related serious adverse events and two serious events (atrial fibrillation, diverticular perforation) judged unrelated to treatment, and three men had four severe events, including a tendon rupture; 21 men (14.7%) had hemoglobin above the upper limit of normal at the final visit.12 At baseline 36% of men took antihypertensive medication, and five (3.2%) started one during the trial; the Kyzatrex label states that antihypertensive treatment and diabetes at baseline were “significant factors related to ambulatory SBP increases”.12,3 The authors name limits: “Representation from diverse racial groups was limited”, and the safety profile is stated “Within the constraints of a 180-day treatment period and 155 treated participants”.12

Table 6.1Doses reported in studies and on labels4 rows
SourceDose reportedRoute and timing
Jatenzo label1Start 237 mg twice daily; adjusted between 158 mg and 396 mg twice dailyOral, with food, morning and evening
Tlando label2225 mg twice daily (two 112.5 mg capsules)Oral, with food, morning and evening
Kyzatrex label3Start 200 mg twice daily; adjusted from 100 mg once in the morning to 400 mg twice dailyOral, with food, morning and evening
Restandol summary of product characteristics (adults including elderly, male hypogonadism)4120 to 160 mg daily for two to three weeks, then 40 to 120 mg daily by clinical effectOral, with a meal; “preferable” that half the daily dose be taken in the morning and half in the evening

The app's typical dose range is 120 to 240 mg, with no interval stated; the three US labels give starting doses of 237 mg, 225 mg and 200 mg twice daily. The Restandol document's initial 120 to 160 mg daily lies inside the app's range and its later 40 to 120 mg daily at or below the range's lower end.4 The mg figures are not interchangeable across products: Jatenzo's 237 mg dose is 150 mg of unesterified testosterone equivalents, and the 2012 Yin studies report doses as testosterone equivalents.5,6

7

Side effects reported

What the labels list

The Jatenzo label lists, among 569 patients in all phase 2 and 3 trials, adverse reactions in more than 2% of polycythemia, diarrhea, dyspepsia, eructation, peripheral edema, nausea, increased hematocrit, headache, prostatomegaly and hypertension.1 In its 4-month study of 166 patients, headache and increased hematocrit each occurred in 8 (4.8%), hypertension in 6 (3.6%; the 2020 paper's table lists 5, 3.0%), decreased HDL in 5 (3.0%) and nausea in 4 (2.4%), and 3 patients (1.8%) stopped for adverse reactions, including rash (1) and headache (2).1,5

In the Tlando label's blood pressure study of 138 men over about four months, hypertension occurred in 7 (5.1%), increased hematocrit in 6 (4.3%) and upper respiratory tract infection in 5 (3.6%), and 4 men (2.9%) stopped for dizziness, weight increase, insomnia or hypertension (2).2

In the Kyzatrex label's study of 155 men, hypertension by cuff measurement was reported in 4 (2.6%), one patient (0.8%) stopped for acne, and hemoglobin increases occurred in 7 (4.5%), while hematocrit was not assessed.3

Blood pressure on the three US labels

Table 7.1Side effects reported3 rows
Product and studyMen24-hour systolic24-hour diastolicLength
Jatenzo label1135 men with acceptable recordings+4.9 mm Hg (95% CI 3.5, 6.4)+2.5 mm Hg (95% CI 1.5, 3.6)Day 139
Tlando label2123 men with acceptable recordings+4.3 mm Hg (95% CI 2.1, 6.5)+1.4 mm Hg (95% CI 0.5, 2.3)About 16 weeks
Kyzatrex label3151 men with acceptable recordings+1.7 mm Hg (95% CI 0.3, 3.1) at 4 months; +1.8 mm Hg (95% CI 0.3, 3.2) at 6 months+0.6 mm Hg (95% CI -0.3, 1.6) at 4 months; +0.6 mm Hg (95% CI -0.4, 1.6) at 6 months4 and 6 months

The Jatenzo label states that “Average blood pressures had not plateaued at the end of the trial”, with ambulatory readings at baseline and day 139, while Bernstein and Dhingra, Marius employees, describe a “demonstrated plateauing” of the Kyzatrex increase between day 120 and day 180.1,12 In an extension of an earlier 12-month Jatenzo trial (129 eligible men, 86 enrolled, 69 completed 24 months in all), Honig and colleagues, three of them at Clarus Therapeutics, report a “3-6 mm Hg increase in systolic blood pressure (P < .05)” and a fall in HDL cholesterol of 9.8 mg/dL (P < .0001), and write that comparative long-term safety “would be strengthened by confirmatory studies versus other TRT formulations”.15

Liver, lipids and hematocrit

The Jatenzo label states that prolonged use of high doses of orally active 17-alpha-alkyl androgens has been associated with serious hepatic adverse effects and that “JATENZO is not known to cause these adverse effects”, and the Kyzatrex label states that the product “is not a 17-alpha-alkyl androgen and is not known to cause hepatic adverse effects”.1,3 In the 2020 Jatenzo trial no clinically significant changes in liver function tests were observed in either group, though three oral patients had AST or ALT rises below twice the upper limit of normal; hematocrit rose in both arms (+5.97 ± 7.46% oral, +4.73 ± 6.65% topical), HDL cholesterol fell 13.91 ± 15.67% on oral testosterone undecanoate against 3.39 ± 16.06% on topical.5

The app lists total testosterone, free testosterone, estradiol, hematocrit, lipids and PSA as its markers for oral testosterone undecanoate. The labels state that serum testosterone is measured 6 hours after the morning dose for Jatenzo, 8 to 9 hours for Tlando and 3 to 5 hours for Kyzatrex.1,2,3

The Jatenzo label states that the product contains testosterone undecanoate, “a Schedule III controlled substance as defined under the Controlled Substances Act”, and the Tlando and Kyzatrex labels carry the same CIII class.1,2,3 The recent-changes entries of the three labels record the removal of a boxed warning on blood pressure increases (07/2025 in each).1,2,3

WADA's 2026 Prohibited List places anabolic agents in class S1, “PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)”, states that “Anabolic agents are prohibited”, and in S1.1 lists testosterone among the anabolic androgenic steroids “when administered exogenously”, together with “other substances with a similar chemical structure or similar biological effect(s) including their esters”.14 The Restandol document states that the product can interfere with anti-doping testing.4

The Jatenzo, Tlando and Kyzatrex labels each state storage at 20°C to 25°C, with excursions permitted to 15°C to 30°C, and each describes dry storage.1,2,3

The Jatenzo and Kyzatrex label texts state no half-life, and the 2012 study could evaluate a testosterone half-life in only about half of its 15 men in the 28-day part.1,3,6 Among the trials described here, the Jatenzo and Tlando phase 3 trials compared oral testosterone undecanoate with topical testosterone, the Kyzatrex trial was single-arm, the Tlando blood pressure study was uncontrolled, the Jatenzo extension followed men from an active-controlled trial, and the 1981 and 2013 trials used placebo; the authors of the Jatenzo extension study write that comparative long-term safety “would be strengthened by confirmatory studies versus other TRT formulations”.5,11,12,8,9,15 The cardiovascular outcomes study that the labels cite, TRAVERSE, tested topical testosterone gel.1

What is the half-life of oral testosterone undecanoate?

The Tlando label states that the elimination half-life of testosterone undecanoate is approximately 2 hours.2 The app uses about 6 hours. A 2012 study of 200 mg as testosterone equivalents twice daily for 28 days reported a median elimination half-life of testosterone of 18.4 hours (mean 29 hours), evaluable in about half of the participants.6 The Tlando label adds that reported half-lives of testosterone in the literature range from 10 to 100 minutes.2

What is the bioavailability of oral testosterone undecanoate?

The Restandol summary of product characteristics states that the bioavailability is about 7%, which equals the app's figure.4

How long does oral testosterone undecanoate take to peak?

The Restandol document states that after a single 80 to 160 mg dose, plasma testosterone peaks approximately 4 to 5 hours after administration.4 The Tlando label gives a median of about 5 hours, against the app's about 4 hours.2 The 2020 Jatenzo trial reports a median of 3.87 hours after the morning dose.5

Does food change how oral testosterone undecanoate is absorbed?

In a single-dose crossover study of 16 hypogonadal men, fasting gave 50% or less of the cumulative exposure of 20% to 50% fat meals, “albeit still substantial”, and a 10% fat meal showed a significant food effect against a 30% fat meal while still exceeding fasting by approximately 50%.7

Does oral testosterone undecanoate raise blood pressure?

In 24-hour ambulatory monitoring, mean systolic pressure rose 4.9 mm Hg (95% CI 3.5 to 6.4; 135 men) on the Jatenzo label, 4.3 mm Hg (2.1 to 6.5; 123 men) on the Tlando label and 1.7 mm Hg at 4 months (0.3 to 3.1; 151 men) on the Kyzatrex label, from trials that differ in length, comparator and dose, and the labels say adverse reaction rates from different trials cannot be directly compared; the Jatenzo trial had a topical comparator (+0.2 mm Hg) and the Kyzatrex trial was single-arm.1,2,3,5,12

Does oral testosterone undecanoate affect the liver?

The Jatenzo label states that the product is not known to cause the serious hepatic adverse effects of prolonged high doses of orally active 17-alpha-alkyl androgens, and the Tlando and Kyzatrex labels state that the product is not a 17-alpha-alkyl androgen.1,2,3

Is oral testosterone undecanoate banned by WADA?

WADA's 2026 Prohibited List lists testosterone in S1.1, anabolic androgenic steroids when administered exogenously, in class S1, which is prohibited at all times, in and out of competition; undecanoate is not named in the list, which also covers “their esters”.14

Is oral testosterone undecanoate a controlled substance?

The US labels classify oral testosterone undecanoate as a Schedule III controlled substance.1,3

14

References

  1. Tolmar Inc. JATENZO (testosterone undecanoate) capsules, for oral use, CIII. DailyMed label, published 15 October 2026 (version 16). DailyMed label
  2. Verity Pharmaceuticals Inc. TLANDO (testosterone undecanoate) capsules, for oral use, CIII. DailyMed label, published 12 March 2026 (version 5). DailyMed label
  3. Marius Pharmaceuticals. KYZATREX (testosterone undecanoate) capsules, for oral use, CIII. DailyMed label, published 8 October 2026 (version 24). DailyMed label
  4. Health Products Regulatory Authority (Ireland). Restandol Testocaps 40 mg soft capsules, Summary of Product Characteristics, 19 February 2020. HPRA SmPC
  5. Swerdloff RS, Wang C, White WB, et al. A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men. J Clin Endocrinol Metab 2020;105:2515-2531. PMC7282712
  6. Yin AY, Htun M, Swerdloff RS, et al. Reexamination of pharmacokinetics of oral testosterone undecanoate in hypogonadal men with a new self-emulsifying formulation. J Androl 2012;33:190-201. PMC4168025
  7. Yin A, Alfadhli E, Htun M, et al. Dietary fat modulates the testosterone pharmacokinetics of a new self-emulsifying formulation of oral testosterone undecanoate in hypogonadal men. J Androl 2012;33:1282-1290. PMC4170073
  8. Skakkebaek NE, Bancroft J, Davidson DW, Warner P. Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study. Clin Endocrinol (Oxf) 1981;14:49-61. PMID 7014044
  9. Bouloux PM, Legros JJ, Elbers JM, et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male 2013;16:38-47. PMID 23581697
  10. White WB, Dobs A, Carson C, et al. Effects of a Novel Oral Testosterone Undecanoate on Ambulatory Blood Pressure in Hypogonadal Men. J Cardiovasc Pharmacol Ther 2021;26:630-637. PMID 34191621
  11. Miner M, Wang C, Kaminetsky J, et al. Safety, efficacy, and pharmacokinetics of oral testosterone undecanoate in males with hypogonadism. Andrology 2025. PMC12006877
  12. Bernstein JS, Dhingra OP. A phase III, single-arm, 6-month trial of a wide-dose range oral testosterone undecanoate product. Ther Adv Urol 2024. PMC11008350
  13. White WB, Bernstein JS, Rittmaster R, Dhingra O. Effects of the oral testosterone undecanoate Kyzatrex on ambulatory blood pressure in hypogonadal men. J Clin Hypertens 2021;23:1420-1430. PMC8678838
  14. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. In force 1 January 2026. WADA Prohibited List 2026
  15. Honig S, Gittelman M, Kaminetsky J, et al. Two-year analysis of a new oral testosterone undecanoate (TU) formulation in hypogonadal men: efficacy, impact on psychosexual function, and safety. J Sex Med 2022;19:1750-1758. PMID 36272969